256 related articles for article (PubMed ID: 32499112)
1. Prediction of human tau 3D structure, and interplay between O-β-GlcNAc and phosphorylation modifications in Alzheimer's disease: C. elegans as a suitable model to study these interactions in vivo.
Ahmad W; Shabbiri K; Ahmad I
Biochem Biophys Res Commun; 2020 Jul; 528(3):466-472. PubMed ID: 32499112
[TBL] [Abstract][Full Text] [Related]
2. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
Liu F; Iqbal K; Grundke-Iqbal I; Hart GW; Gong CX
Proc Natl Acad Sci U S A; 2004 Jul; 101(29):10804-9. PubMed ID: 15249677
[TBL] [Abstract][Full Text] [Related]
3. Identification of O-GlcNAc sites within peptides of the Tau protein and their impact on phosphorylation.
Smet-Nocca C; Broncel M; Wieruszeski JM; Tokarski C; Hanoulle X; Leroy A; Landrieu I; Rolando C; Lippens G; Hackenberger CP
Mol Biosyst; 2011 May; 7(5):1420-9. PubMed ID: 21327254
[TBL] [Abstract][Full Text] [Related]
4. O-GlcNAc modification of tau directly inhibits its aggregation without perturbing the conformational properties of tau monomers.
Yuzwa SA; Cheung AH; Okon M; McIntosh LP; Vocadlo DJ
J Mol Biol; 2014 Apr; 426(8):1736-52. PubMed ID: 24444746
[TBL] [Abstract][Full Text] [Related]
5. The potential role of tau protein O-glycosylation in Alzheimer's disease.
Robertson LA; Moya KL; Breen KC
J Alzheimers Dis; 2004 Oct; 6(5):489-95. PubMed ID: 15505370
[TBL] [Abstract][Full Text] [Related]
6. Mapping O-GlcNAc modification sites on tau and generation of a site-specific O-GlcNAc tau antibody.
Yuzwa SA; Yadav AK; Skorobogatko Y; Clark T; Vosseller K; Vocadlo DJ
Amino Acids; 2011 Mar; 40(3):857-68. PubMed ID: 20706749
[TBL] [Abstract][Full Text] [Related]
7. Role of glycosylation in hyperphosphorylation of tau in Alzheimer's disease.
Liu F; Zaidi T; Iqbal K; Grundke-Iqbal I; Merkle RK; Gong CX
FEBS Lett; 2002 Feb; 512(1-3):101-6. PubMed ID: 11852060
[TBL] [Abstract][Full Text] [Related]
8. Neurofibrillary tangles and tau phosphorylation.
Brion JP; Anderton BH; Authelet M; Dayanandan R; Leroy K; Lovestone S; Octave JN; Pradier L; Touchet N; Tremp G
Biochem Soc Symp; 2001; (67):81-8. PubMed ID: 11447842
[TBL] [Abstract][Full Text] [Related]
9. Production of O-GlcNAc Modified Recombinant Tau in E. coli and Detection of Ser400 O-GlcNAc Tau In Vivo.
Yuzwa SA; Vocadlo DJ
Methods Mol Biol; 2017; 1523():237-248. PubMed ID: 27975253
[TBL] [Abstract][Full Text] [Related]
10. MARKing tau for tangles and toxicity.
Drewes G
Trends Biochem Sci; 2004 Oct; 29(10):548-55. PubMed ID: 15450610
[TBL] [Abstract][Full Text] [Related]
11. O-GlcNAcylation: A regulator of tau pathology and neurodegeneration.
Gong CX; Liu F; Iqbal K
Alzheimers Dement; 2016 Oct; 12(10):1078-1089. PubMed ID: 27126545
[TBL] [Abstract][Full Text] [Related]
12. Phosphorylation that detaches tau protein from microtubules (Ser262, Ser214) also protects it against aggregation into Alzheimer paired helical filaments.
Schneider A; Biernat J; von Bergen M; Mandelkow E; Mandelkow EM
Biochemistry; 1999 Mar; 38(12):3549-58. PubMed ID: 10090741
[TBL] [Abstract][Full Text] [Related]
13. Involvement of aberrant glycosylation in phosphorylation of tau by cdk5 and GSK-3beta.
Liu F; Iqbal K; Grundke-Iqbal I; Gong CX
FEBS Lett; 2002 Oct; 530(1-3):209-14. PubMed ID: 12387894
[TBL] [Abstract][Full Text] [Related]
14. Evidence for an imbalance between tau O-GlcNAcylation and phosphorylation in the hippocampus of a mouse model of Alzheimer's disease.
Gatta E; Lefebvre T; Gaetani S; dos Santos M; Marrocco J; Mir AM; Cassano T; Maccari S; Nicoletti F; Mairesse J
Pharmacol Res; 2016 Mar; 105():186-97. PubMed ID: 26816085
[TBL] [Abstract][Full Text] [Related]
15. OGlcNAcylation and phosphorylation have opposing structural effects in tau: phosphothreonine induces particular conformational order.
Brister MA; Pandey AK; Bielska AA; Zondlo NJ
J Am Chem Soc; 2014 Mar; 136(10):3803-16. PubMed ID: 24559475
[TBL] [Abstract][Full Text] [Related]
16. Flavonoids from Stems and Leaves of
Shengkai D; Yazhen S
CNS Neurol Disord Drug Targets; 2022; 21(4):367-374. PubMed ID: 34455972
[TBL] [Abstract][Full Text] [Related]
17. Reduction of O-linked N-acetylglucosamine-modified assembly protein-3 in Alzheimer's disease.
Yao PJ; Coleman PD
J Neurosci; 1998 Apr; 18(7):2399-411. PubMed ID: 9502801
[TBL] [Abstract][Full Text] [Related]
18. Glycosylation of microtubule-associated protein tau in Alzheimer's disease brain.
Takahashi M; Tsujioka Y; Yamada T; Tsuboi Y; Okada H; Yamamoto T; Liposits Z
Acta Neuropathol; 1999 Jun; 97(6):635-41. PubMed ID: 10378383
[TBL] [Abstract][Full Text] [Related]
19. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau.
Brandt R; Gergou A; Wacker I; Fath T; Hutter H
Neurobiol Aging; 2009 Jan; 30(1):22-33. PubMed ID: 17590239
[TBL] [Abstract][Full Text] [Related]
20. Early phosphorylation of tau in Alzheimer's disease occurs at Ser-202 and is preferentially located within neurites.
Su JH; Cummings BJ; Cotman CW
Neuroreport; 1994 Nov; 5(17):2358-62. PubMed ID: 7533559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
